The JAK-STAT Pathway and Graft-vs-Host Disease

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Graft vs Host Disease

Managing GVHD

GVHD Pathobiology: Phase 1

JAKs and APC Activation

GVHD Pathobiology: Phase 2

Cytokines Drive Cellular Differentiation

JAKs and GVHD

IFNγ Receptor Knockout GVHD Mouse Model

T-Regulatory Cells

Chemokines

Disruption of IFNγ Signaling Through JAK1/JAK2

Cytokine Signaling Through the JAK-STAT Pathway

Phase 2 and JAKs

GVHD Pathobiology: Phase 3

Immune Regulation of Acute GVHD

JAKs and Chronic GVHD

Clinical Activity of JAK Inhibitors

Key Takeaways

Abbreviations

Abbreviations (cont)